diff --git a/domains/health/OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md b/domains/health/OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md index 183513621..0e784d6e6 100644 --- a/domains/health/OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md +++ b/domains/health/OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md @@ -17,6 +17,12 @@ What makes this significant is the adoption speed. Reaching 40% of US physicians The incumbent response is UpToDate ExpertAI (Wolters Kluwer, Q4 2025), leveraging its trusted brand and install base. The competitive dynamic -- startup vs incumbent in clinical decision support -- will determine whether AI clinical knowledge becomes a winner-take-all market or fragments. + +### Additional Evidence (extend) +*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-18* + +OpenEvidence reached 20M clinical consultations/month by January 2026 (2,000%+ YoY growth from 8.5M/month in 2025), achieved 1M consultations in a single day on March 10, 2026, and is used across 10,000+ hospitals. Valuation tripled from $3.5B to $12B in months. First AI to score 100% on all parts of USMLE. Despite this scale, 44% of physicians remain concerned about accuracy/misinformation and 19% about lack of oversight—trust barriers persist even among heavy users. + --- Relevant Notes: diff --git a/domains/health/healthcare AI funding follows a winner-take-most pattern with category leaders absorbing capital at unprecedented velocity while 35 percent of deals are flat or down rounds.md b/domains/health/healthcare AI funding follows a winner-take-most pattern with category leaders absorbing capital at unprecedented velocity while 35 percent of deals are flat or down rounds.md index 0ce31982a..1f05cd5ad 100644 --- a/domains/health/healthcare AI funding follows a winner-take-most pattern with category leaders absorbing capital at unprecedented velocity while 35 percent of deals are flat or down rounds.md +++ b/domains/health/healthcare AI funding follows a winner-take-most pattern with category leaders absorbing capital at unprecedented velocity while 35 percent of deals are flat or down rounds.md @@ -25,6 +25,12 @@ The emerging consensus: healthcare AI is a platform shift, not a bubble, but the Abridge raised $300M Series E at $5B valuation and Ambiance raised $243M Series C at $1.04B valuation by early 2026, demonstrating the capital concentration in category leaders. Function Health's $300M Series C at $2.2B valuation further confirms winner-take-most dynamics in health AI. + +### Additional Evidence (confirm) +*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-18* + +OpenEvidence raised $250M Series D at $12B valuation (January 2026), doubling valuation in 3 months from $6B and tripling from $3.5B earlier. This represents the fastest capital absorption in clinical AI history for a single category leader (clinical reasoning/decision support), while the company achieved 2,000%+ YoY consultation growth. + --- Relevant Notes: diff --git a/domains/health/medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md b/domains/health/medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md index da1625c12..8a51b85ef 100644 --- a/domains/health/medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md +++ b/domains/health/medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md @@ -17,6 +17,12 @@ A deeper finding from a Stanford/Harvard study challenges even the "similar accu The implication for AI deployment strategy: the highest-value clinical AI applications are not diagnostic augmentation but workflow automation (ambient documentation, administrative burden reduction) and safety netting (AI triage catching missed findings). The centaur model may still apply to medicine, but the interaction design must prevent physicians from overriding AI on tasks where AI demonstrably outperforms -- a politically and ethically charged constraint. + +### Additional Evidence (challenge) +*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-18* + +OpenEvidence achieved 100% USMLE score (first AI in history) and reached 20M monthly consultations with 40%+ of US physicians using it daily across 10,000+ hospitals. This creates the first large-scale empirical test of whether benchmark performance translates to population health outcomes. The absence of published outcomes data at this scale represents a critical gap—if benchmark superiority doesn't produce measurable clinical impact at 20M consultations/month, it would strongly confirm the benchmark-outcomes disconnect. + --- Relevant Notes: diff --git a/inbox/queue/2026-01-01-openevidence-clinical-ai-growth-12b-valuation.md b/inbox/queue/2026-01-01-openevidence-clinical-ai-growth-12b-valuation.md index f865ea6e2..86ae97de4 100644 --- a/inbox/queue/2026-01-01-openevidence-clinical-ai-growth-12b-valuation.md +++ b/inbox/queue/2026-01-01-openevidence-clinical-ai-growth-12b-valuation.md @@ -7,9 +7,13 @@ date: 2026-01-01 domain: health secondary_domains: [ai-alignment] format: company-announcement -status: unprocessed +status: enrichment priority: medium tags: [openevidence, clinical-ai, decision-support, physician-adoption, clinical-decision-support, health-ai, trust] +processed_by: vida +processed_date: 2026-03-18 +enrichments_applied: ["OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md", "medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md", "healthcare AI funding follows a winner-take-most pattern with category leaders absorbing capital at unprecedented velocity while 35 percent of deals are flat or down rounds.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -68,3 +72,13 @@ This creates a two-track clinical AI story: (1) Abridge/ambient scribes for docu PRIMARY CONNECTION: [[OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years]] WHY ARCHIVED: Significant scale update — the existing claim understates 2026 metrics by an order of magnitude. Also: USMLE 100% creates the benchmark vs. outcomes tension in practice, not theory. EXTRACTION HINT: Update the existing claim with scale metrics, but flag the benchmark-to-outcomes translation tension as a challenge to both the OpenEvidence claim and the benchmark performance claim + + +## Key Facts +- OpenEvidence valued at $12B as of January 2026 Series D +- OpenEvidence processes 20M clinical consultations/month as of January 2026 +- OpenEvidence reached 1M consultations in one day on March 10, 2026 +- 44% of physicians concerned about AI accuracy and misinformation risk +- 19% of physicians concerned about lack of physician oversight or explainability +- OpenEvidence used across 10,000+ hospitals nationwide +- Series D led by Thrive Capital and DST Global